Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Theresa May

- PMLiVE

UK business: Brexit deadlock causing “frustration and anger”

Pharma must still plan for no-deal, only slightly later

- PMLiVE

Investments show UK biotech still booming despite Brexit

UK raised a quarter of all European biotech funds

- PMLiVE

Pharma fears “lack of focus” on no-deal Brexit preparations

As Brexit is delayed, pharma suggests new measures to avoid no-deal drugs shortages

- PMLiVE

Is May’s Brexit deal sinking after Speaker’s procedural torpedo?

Life sciences firms must keep planning for no-deal - for now

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

More Brexit chaos as government suffers more defeats

UK parliament rejects a no-deal Brexit

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

Brexit deal defeated again, crucial no-deal vote awaits

UK pharma urges no-deal to be ruled out

- PMLiVE

Shionogi planning HQ move from UK

Brexit understood to be main reason for switch

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links